Bletilol B is primarily used in research settings for its potential cardiovascular effects. It has been investigated for its ability to modulate cardiac ion channels, particularly potassium and calcium channels, making it a compound of interest in the study of arrhythmias and other heart rhythm disorders. Due to its structural properties, it serves as a lead compound in the development of new antiarrhythmic agents. Additionally, Bletilol B has shown inhibitory activity against certain enzymes involved in inflammatory pathways, suggesting possible applications in treating inflammatory-related cardiovascular conditions. Its use remains largely experimental, with ongoing studies to determine its efficacy and safety profile in preclinical models.